Friday, 14 Dec 2018

You are here

Pilot Data on Rituximab in Henoch-Schonlein Purpura

Management of Henoch-Schonlein purpura (HSP) can be challenging as supportive care and avoidance of corticosteroids (CS) are often insufficient options. A new series of case reports and literature review of steroid refractory HSP suggests that rituximab (RTX) may be effective in reducing hospital admissions, overall steroid use, and is capable of inducing remission.

A minority of HSP cases are so severe with either persistent rash, arthritis, abdominal involvement, or renal disease, that CS are needed. Other alternatives for steroid sparing are few.

Crayne et al describes 8 children treated with RTX for chronic refractory HSP.  Patients were identified by retrospective review of data between 2006–2014 at a single institution.

Prior to RTX, 7/8 had at least one hospitalization for HSP (median 1.5, range 0–3).

Following RTX, only 2/8 were hospitalized.  With RTX use, oral CS use fell significantly from 0.345 mg/kg/day before RTX to 0 mg/kg/day at 6 months (p = 0.078), 1 year (p = 0.0625), and 2 years (p = 0.03) following RTX infusion.

Ultimately 7/8 remission criteria (no active rash, arthritis, nephritis (hematuria or proteinuria), or gastrointestinal involvement). 

The authors also describe another eight, mostly single case, reports of RTX use in adults and children with HSP - all with beneficial outcomes. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Genetic Diagnosis for Previously Undiagnosed Disorders

The NEJM has reported the NIH's Undiagnosed Diseases Network (UDN) study results of genetically identifying new diseases from prospectively followed persons with undiagnosed disorders. The UDN was formed in 2014 as a network of seven clinical sites, two sequencing cores, a coordinating center, central biorepository, a metabolomics core, and a model organisms screening center. It was established to apply a multidisciplinary model in the evaluation of the most challenging cases and to identify the biologic characteristics of newly discovered diseases.

SLE and Risk of Malignancy

The risk for cancer in systemic lupus erythematosus (SLE) patients has been inconsistently studied.  A new metanalysis shows that SLE has an increased risk for 16 specific cancers and decreased risk for prostate cancer and cutaneous melanoma. 

The Benefits of a Lupus Clinic

A comparative cohort study assessing the quality of care in patients with systemic lupus erythematosus (SLE) suggests that a dedicated lupus clinic has better quality measure performance compared to lupus management in a general rheumatology clinic.

A study from Rush University enrolled 150 consecutive SLE patients - with 73 followed in the general rheumatology clinic and 77 followed in a dedicated lupus clinic. 

Diagnosing Early Lupus from Mimics

A multicenter study of early systemic lupus erythematosus (SLE) patients examined manifestations at disease onset and found that certain clinical features can help to distinguish early SLE from other SLE‐mimicking conditions. 

High CV Risk in Lupus

Patients with systemic lupus erythematosus (SLE) remain at risk for accelerated atherosclerosis, and important questions have yet to be answered, British investigators reported.